Participating Companies

Acesion Pharma
A Dan­ish biotech com­pany found­ed in 2011 and based in Copen­ha­gen. Ace­sion Phar­ma de­vel­ops more ef­fi­ca­cious and safe SK chan­nel in­hibi­tor molecules for the sus­tained and long-term treat­ment of atrial fib­ril­la­tion (AF), the most com­mon type of car­di­ac ar­rhyth­mia. [more in­for­ma­tion]
Unique, in­te­grat­ed biotech com­pany with a strong pedi­gree and am­bi­tious pipe­line of mar­ket­ed and clin­i­cal-stage al­bu­min-en­abled ther­a­peu­tics de­vel­oped with part­n­ers, in­clud­ing among others CSL Behring, Mer­ck and GSK. Al­bumedix is cre­at­ing a pipe­line of pro­pri­e­tary and co-de­vel­oped al­bu­min-en­abled ther­a­pies. [more in­for­ma­tion]
BioPorto [CPH: BIOPOR]
Bio­Por­to Di­ag­nos­tics A/S is an in-vit­ro di­ag­nos­tics com­pany that pro­vides health­care pro­fes­sio­n­als in clin­i­cal and re­search sett­ings a range of di­ag­nos­tic tests and anti­bodies. With key ex­per­tise in bio­mark­er de­tec­tion, Bio­Por­to has a deep port­fo­lio of di­ag­nos­tic aides for the re­search sett­ing. [more in­for­ma­tion]
Galecto Biotech [GLTO] $106 MM MCap
A Swedish com­pany found­ed in 2011 by lead­ing galectin sci­en­tists and biotech ex­ecu­tives from Swe­den, Unit­ed King­dom, and Den­mark. The com­pany builds on more than 10 years of re­search in­to galectins and galectin mo­d­u­la­tors, which com­bined with a strong pa­tent es­tate gives Galec­to Biotech a unique plat­form. Their galectin-3 in­hibi­tor for IPF is Phase 2b ready. [more in­for­ma­tion]
IO Biotech
IO Biotech is a clin­i­cal stage biotech com­pany de­vel­op­ing dis­rup­tive im­mune ther­a­pies for the treat­ment of can­cer. The pipe­line of first-in-class im­mune mo­d­u­lat­ing an­ti-can­cer ther­a­pies is de­vel­oped by a unique tech­nol­o­gy plat­form, T-win®, en­abling the ac­ti­va­tion of T cells that are spe­cif­ic for im­mune-sup­pres­sive molecules. [more in­for­ma­tion]
LEO Science & Tech Hub
Their mis­sion is to ex­plore cutt­ing-edge sci­ence and tech­nol­o­gy op­por­tu­ni­ties with rel­e­vance for der­ma­tol­o­gy. They are an ex­pe­ri­enced team with a pas­sion for re­search. They part­n­er with public and pri­vate in­sti­tu­tions to estab­lish close col­lab­o­ra­tions with a fo­cus on what could be pos­si­ble. [more in­for­ma­tion]
Lundbeckfonden Ventures
Lund­beck­fon­den Ven­tures is an ev­er­green life sci­ence ven­ture fund in­vest­ing in­ter­na­tio­n­al­ly in health­care com­pa­nies. They pri­mar­i­ly in­vest in clin­i­cal pro­jects and com­pa­nies with new tech­nol­o­gy plat­forms and are par­tic­u­lar­ly in­ter­est­ed in spe­cial­ist prod­uct op­por­tu­ni­ties. [more in­for­ma­tion]
The so­lu­tion (MT-100) au­to­mates bed­side pro­duc­tion and in­fu­sion of the trac­er O-15 H2O (gold stan­dard). MT-100 (planned launch in 2019) will out­per­form al­ter­na­tive trac­ers on ac­cu­ra­cy, ef­fi­cien­cy and safe­ty. Ini­tial fo­cus on car­di­ol­o­gy and sub­se­quent­ly the tech­nol­o­gy plat­form can be ap­plied to on­col­o­gy, neu­rol­o­gy and en­docri­nol­o­gy. [more in­for­ma­tion]
Pur­su­ing the de­vel­op­ment of a nov­el vaccine can­di­date against Group B Strep­to­coc­ci (GBS). Pos­i­tive Phase I re­sults Jan­uary 2017 in 240 healthy wo­m­en. [more in­for­ma­tion]
NMD Pharma ApS
The com­pany has iden­ti­fied a nov­el dis­ease tar­get and de­vel­oped new small molecule drug-like com­pounds ef­fec­tive­ly in­creas­ing neu­ro­mus­cu­lar trans­mis­sion. [more in­for­ma­tion]
Novo A/S [NVOS] $48 MM MCap
No­vo A/S ma­n­ages pro­pri­e­tary fixed in­come and equi­ty as­sets on be­half of the No­vo group. The firm out­sources the equi­ty in­vest­ments to ex­ter­nal ma­n­agers. No­vo A/S is a biotech­nol­o­gy ven­ture cap­i­tal in­ves­tor. [more in­for­ma­tion]
Nuevolution [NUE.ST]
Scan­di­na­vian bio­phar­ma­ceu­ti­cal com­pany fo­cused on de­vel­op­ing drug treat­ments for hu­man dis­eas­es within on­col­o­gy and chron­ic in­flam­ma­to­ry dis­eas­es. We have set our fo­cus and ob­jec­tives to be: Re­al­iza­tion of ef­fi­ca­cious, safer, tablet based, and low­er cost medicines, for treat­ment of se­vere chron­ic in­flam­ma­to­ry dis­eas­es like e.g. [more in­for­ma­tion]
Oncology Venture [ONCGF] $25 MM MCap
Ded­i­cat­ed to un­lock the po­ten­tial of on­col­o­gy prod­ucts that has shown ef­fi­ca­cy but not enough to beat the gold stan­dard – to im­prove the ef­fi­ca­cy of the drugs, in­crease the re­sponse rate in can­cer pa­tients, re­duce time­lines and through this im­prove suc­cess rates in On­col­o­gy Drug De­vel­op­ment. [more in­for­ma­tion]
Orphazyme [ORPH] $164 MM MCap
Or­p­hazyme A/S is a Dan­ish biotech com­pany. It is en­gaged in the de­vel­op­ment of paradigm-chang­ing medicines for the treat­ment of pro­tein mis­fold­ing dis­eas­es. The com­pany's lead can­di­date, ari­mo­clo­mol, is in de­vel­op­ment for four se­vere or­phan dis­eas­es; [more in­for­ma­tion]
De­vel­oped the easy to use Leu­co­Patch® De­vice and pro­cess so that clini­cians can of­fer au­tol­o­gous ac­tive cell ther­a­py to pa­tients so that they can help to heal them­selves. [more in­for­ma­tion]
Saniona [SANION:ST] SKr933 MM MCap
A re­search and de­vel­op­ment com­pany fo­cused on drugs for dis­eas­es of the cen­tral ner­vous sys­tem, au­toim­mune dis­eas­es, metabolic dis­eas­es and treat­ment of pain. The com­pany has a sig­ni­f­i­cant port­fo­lio of po­ten­tial drug can­di­dates at pre-clin­i­cal and clin­i­cal stage. [more in­for­ma­tion]
UNION therapeutics A/S
UNION ther­a­peu­tics A/S (former­ly Antibio Tx is a pri­vate­ly held, clin­i­cal stage, phar­ma­ceu­ti­cal com­pany. De­vel­op­ing ov­el medicine for pa­tients with an un­met need. UNION’s chem­istry plat­form uti­l­izes di­rect im­muno­mo­d­u­la­to­ry and mi­cro­bi­o­log­i­cal ef­fects, en­abling treat­ments across a ver­satile range of in­di­ca­tions [more in­for­ma­tion]